CARE Edge Reports Zero Deviation in Symbiotec Pharmalab's IPO Proceeds Utilization
Symbiotec Pharmalab Ltd · Others (Uncategorized) · 06 Nov 2026, 2:04 am
CARE Edge Reports Zero Deviation in Symbiotec Pharmalab's IPO Proceeds Utilization CARE Edge Ratings issued its Monitoring Agency report for Symbiotec Pharmalab for the quarter ended 30th Sep'26, confirming zero deviation from stated IPO objectives. Out of ₹150.00 crore raised via fresh issue proceeds, the company deployed ₹143.59 crore during the quarter. Key capital allocations include ₹112.50 crore fully utilized for debt prepayment/repayment, ₹29.50 crore deployed for general corporate working capital requirements (out of ₹29.53 crore allocated), and ₹1.59 crore toward offer-related expenses. Unutilized funds totaling ₹6.41 crore remain parked in designated bank accounts.
Original exchange filing (PDF)
More announcements from Symbiotec Pharmalab Ltd
- Intimation regarding change in Corporate Identification Number (CIN) and Listing Status of the Company. · 17 Nov 2026
- Transcript of the Earnings conference call for the Analysts and Investors for the Quarter and Half year ended · 12 Nov 2026
- Pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time .... · 12 Nov 2026
- Pursuant to Part A of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Audio recording of Conference Call for Analysts and Investors held on November .... · 06 Nov 2026
- Symbiotec Signs 10 Year take or Pay Agreement to Manufacture Fermentation based alternative protein for EU Innovator · 06 Nov 2026
- The Investor release being issued by the company, for the quarter and half year ended September 30, 2026 · 06 Nov 2026
- Pursuant to regulations 30 of the SEBI Listing Regulations, Investor Presentation on the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year ended September 30, 2026. · 06 Nov 2026
- Symbiotec Pharmalab Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 06 Nov 2026
